Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of AZD5004 Formulations
NCT06996886Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- May 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of elecoglipron in type 2 diabetes mellitus (T2DM) and obesity (4 arms), sponsored by AstraZeneca. Primary endpoints: Area under concentration-time curve from time 0 to infinity, Area under concentration-curve from time 0 to the last quantifiable concentration and 4 more. Started May 2025; status: completed.
02
Drugs
elecoglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT06996886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06996886.